We’re inching closer to a new vaccine for Lyme disease. But will the public accept it?

ca nid ixodes scapularis online
Image: iStock.com/Dietrerm Meyrl

As the threat of Lyme disease grows and fears surrounding it spread faster than the ticks that carry the infection, researchers are developing two vaccine or vaccine-like approaches to prevent this increasingly problematic disease. But don’t expect to get one soon. They are at least three to five years away from clinical use, according to their developers.

That may seem like a long time to wait… . But it’s taken researchers almost two decades to get this close — for the second time. Developers have faced an uphill battle since LYMErix, a short-lived human vaccine, was pulled from the market in 2002 amid low demand and lawsuits over potential side effects, not to mention mounting distrust in vaccines.

Related article:  We've almost eradicated Polio. But recent measles outbreaks show us why the battle isn't over.

As work moves forward on these two new approaches, here’s the question on many minds: Is the market ready for a new Lyme disease vaccine?

ADVERTISEMENT

One of the new approaches is a vaccine, which works by stimulating the immune system to make antibodies that can attack Borrelia burgdorferi and other types of Borrelia, the bacteria that cause Lyme disease. The other is an injection of a single antibody.

Read full, original post: Can a New Lyme Disease Vaccine Overcome a History of Distrust and Failure?

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend